CarrBR, WilsonJD. Disorders of the ovary and female reproductive tract. IsselbacherKJ, BraunwaldE, WilsonJDet al.Harrison's principles of internal medicine, 13th. New York: McGraw-Hill, 1994; 2033–2034.
ColNF, EckmanMH, KarasRHet al.Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA, 1997; 277:1140–1147.
5.
HulleyS, GradyD, BushTet al.Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 1998; 280:605–613.
6.
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002; 288:321–333.
7.
BrettAS, CarneyPI, McKeownRE. Attitudes toward hormone therapy after the Women's Health Iniative: A comparison of internists and gynecologists. J Gen Intern Med, 2005; 20:416–418.
8.
HershAL, StefanickML, StaffordRS. National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA, 2004; 291:47–53.
9.
HaysJ, OckeneJK, BrunnerRLet al.Effects of estrogen plus progestin on health-related quality of life. N Engl J Med, 2003; 348:1839–1854.
10.
ShumakerSA, LegaultC, RappSRet al.Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenpausal women. The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA, 2003; 289:2651–2662.
11.
RappSR, EspelandMA, ShumakerSAet al.Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA, 2003; 289:2663–2672.
12.
HendrixSL, CochraneBB, NygaardIEet al.Effects of estrogen with and without progestin on urinary incontinence. JAMA, 2005; 293:935–948.
13.
The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA, 2004; 291:1701–1712.
14.
BrunnerRL, GassM, AragakiAet al.Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: Results from the Women's Health Initiative randomized clinical trial. Arch Intern Med, 2005; 165:1976–1986.
15.
ShumakerSA, LegaultC, KullerLet al.Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA, 2004; 291:2947–2958.
16.
EspelandMA, RappSR, ShumakerSAet al.Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA, 2004; 291:2959–2968
17.
LakeySL, ReedSD, LaCroixAZ, GrothausL, NewtonKM. Self-reported changes in providers' hormone therapy prescribing and counseling practices after the Women's Health Initiative. J Womens Health, 2010; 19:2175–2181.
18.
PowerML, BaronJ, SchulkinJ. Factors associated with obstetrician-gynecologists' response to the Women's Health Initiative trial of combined hormone therapy. Med Decis Making, 2008; 28:411–418.
19.
PowerML, AndersonBL, SchulkinJ. Attitudes of obstetrician-gynecologists toward the evidence from the WHI HT trials remain generally skeptical. Menopause, 2009; 16:500–508.
20.
MansonJE, BassukSS. Invited commentary: Hormone therapy and risk of coronary heart disease—Why renew the focus on the early years of menopause?Am J Epidemiol, 2007; 166:511–517.
21.
Barrett-ConnerE. Hormones and heart disease in women: The timing hypothesis. Am J Epidemiol, 2007; 166:506–510.
22.
BanksE, CanfellK. Invited commentary: Hormone therapy risks and benefits—The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Am J Epidemiol, 2009; 170:24–28.
23.
PrenticeRL, MansonJE, LangerRDet al.Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol, 2009; 170:12–23.
24.
TohS, Hernandez-DiazS, LoganR, RossouwJE, HernanMA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: Does the increased risk ever disappear?Ann Intern Med, 2010; 152:211–217.
25.
HarmonSM, BrintonEA, CedarsMet al.KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric, 2005; 8:3–12.
26.
ELITE: Early versus Late Intervention Trial with Estradiol. clinicaltrials.gov/ct2/show/NCT00114517. 2010 October 7.
27.
YabroffKR, SaraiyaM, MeissnerHIet al.Specialty differences in primary care physician reports of Papanicolaou test screening practices: A national survey, 2006 to 2007. Ann Intern Med, 2009; 151:602–611.
28.
U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: Recommendations and rationale. Ann Intern Med, 2002; 137:526–528.
29.
EpsteinAM. Geographic variation in Medicare spending. N Engl J Med, 2010; 363:85–86.
